Free Trial

Biomerica (BMRA) Competitors

Biomerica logo
$3.39 +0.02 (+0.56%)
As of 11:09 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BMRA vs. KALA, OKUR, ESLA, BDRX, MAAQ, RANI, MRNS, SNYR, ALLK, and INKT

Should you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include KALA BIO (KALA), OnKure Therapeutics (OKUR), Estrella Immunopharma (ESLA), Biodexa Pharmaceuticals (BDRX), Mana Capital Acquisition (MAAQ), Rani Therapeutics (RANI), Marinus Pharmaceuticals (MRNS), Synergy CHC (SNYR), Allakos (ALLK), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry.

Biomerica vs. Its Competitors

Biomerica (NASDAQ:BMRA) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

KALA BIO has a net margin of 0.00% compared to Biomerica's net margin of -85.42%. Biomerica's return on equity of -85.90% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
Biomerica-85.42% -85.90% -61.06%
KALA BIO N/A -369.29%-64.99%

Biomerica has higher revenue and earnings than KALA BIO. Biomerica is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biomerica$5.41M1.60-$5.98M-$2.32-1.46
KALA BIO$3.89M10.70-$38.51M-$8.24-0.78

In the previous week, KALA BIO had 1 more articles in the media than Biomerica. MarketBeat recorded 4 mentions for KALA BIO and 3 mentions for Biomerica. Biomerica's average media sentiment score of 0.65 beat KALA BIO's score of -0.17 indicating that Biomerica is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biomerica
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
KALA BIO
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 15.0% of Biomerica shares are owned by insiders. Comparatively, 8.3% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Biomerica has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, KALA BIO has a beta of -1.88, meaning that its share price is 288% less volatile than the S&P 500.

KALA BIO has a consensus target price of $13.50, suggesting a potential upside of 109.14%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts plainly believe KALA BIO is more favorable than Biomerica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomerica
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
KALA BIO
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Biomerica and KALA BIO tied by winning 8 of the 16 factors compared between the two stocks.

Get Biomerica News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMRA vs. The Competition

MetricBiomericaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.64M$2.43B$5.59B$9.00B
Dividend YieldN/A1.80%5.25%4.03%
P/E Ratio-1.469.3627.5420.18
Price / Sales1.60603.19415.83171.78
Price / CashN/A161.3437.0657.97
Price / Book1.084.658.105.61
Net Income-$5.98M$31.26M$3.17B$248.59M
7 Day Performance2.54%6.39%3.33%4.67%
1 Month Performance-1.20%3.65%3.54%7.18%
1 Year Performance1.61%2.23%33.62%21.21%

Biomerica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMRA
Biomerica
0.39 of 5 stars
$3.39
+0.6%
N/A-1.6%$8.64M$5.41M-1.4660
KALA
KALA BIO
3.676 of 5 stars
$5.28
+3.5%
$13.50
+155.7%
-11.4%$32.91M$3.89M-0.6430News Coverage
Gap Up
OKUR
OnKure Therapeutics
2.8606 of 5 stars
$2.39
+0.4%
$32.33
+1,252.9%
N/A$32.15MN/A-0.45N/A
ESLA
Estrella Immunopharma
2.239 of 5 stars
$0.88
+0.2%
$16.00
+1,714.7%
-22.1%$31.83MN/A-3.39N/AGap Up
BDRX
Biodexa Pharmaceuticals
N/A$0.87
+0.8%
N/AN/A$31.38M$470K0.0020Upcoming Earnings
MAAQ
Mana Capital Acquisition
N/A$3.80
+3.3%
N/A+588.5%$30.88MN/A0.001
RANI
Rani Therapeutics
1.4904 of 5 stars
$0.54
+0.2%
$7.33
+1,267.4%
-80.9%$30.78M$1.20M-0.54110Gap Up
MRNS
Marinus Pharmaceuticals
2.3622 of 5 stars
$0.55
-0.2%
$3.92
+613.3%
-56.1%$30.32M$30.99M-0.22110
SNYR
Synergy CHC
3.2255 of 5 stars
$3.37
+4.0%
$10.00
+196.7%
N/A$29.79M$34.83M0.0040
ALLK
Allakos
3.0325 of 5 stars
$0.33
flat
$2.00
+507.7%
N/A$29.74MN/A-0.16190
INKT
MiNK Therapeutics
2.6985 of 5 stars
$7.28
+0.6%
$37.50
+415.5%
-14.4%$28.82MN/A-2.8930Gap Up

Related Companies and Tools


This page (NASDAQ:BMRA) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners